Abstract
Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.
Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.
Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.
CNS & Neurological Disorders - Drug Targets
Title:Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases
Volume: 17 Issue: 9
Author(s): Kin Yen Chia, Khuen Yen Ng, Rhun Yian Koh and Soi Moi Chye*
Affiliation:
- Applied Biomedical Science and Biotechnology, International Medical University, Kuala Lumpur,Malaysia
Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.
Abstract: Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.
Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.
Export Options
About this article
Cite this article as:
Chia Yen Kin, Ng Yen Khuen , Koh Yian Rhun and Chye Moi Soi*, Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases, CNS & Neurological Disorders - Drug Targets 2018; 17 (9) . https://dx.doi.org/10.2174/1871527317666180315161626
DOI https://dx.doi.org/10.2174/1871527317666180315161626 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Changes in Speech Chunking in Reading Aloud is a Marker of Mild Cognitive Impairment and Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study
Current Vascular Pharmacology Role of Ligand-Based Drug Design Methodologies toward the Discovery of New Anti- Alzheimer Agents: Futures Perspectives in Fragment-Based Ligand Design
Current Medicinal Chemistry Cholinesterase Inhibitory Potential of Quercetin towards Alzheimer’s Disease - A Promising Natural Molecule or Fashion of the Day? - A Narrowed Review
Current Neuropharmacology Editorial (How Natural is it for Nature to Help with Major Depressive Disorder?)
CNS & Neurological Disorders - Drug Targets Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism Navigating the Sea Changes in Patent Law to Successfully Build Value
Technology Transfer and Entrepreneurship (Discontinued) Synthetic Lethality-Based Therapeutics: Perspectives for Applications in Colorectal Cancer
Current Cancer Drug Targets History of Psychiatry in the Dominican Republic
Adolescent Psychiatry Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy
Current Neuropharmacology Glycosomal Targets for Anti-Trypanosomatid Drug Discovery
Current Medicinal Chemistry Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Editorial: Glia-Neuron Crosstalk and its Therapeutic Implication in Neuropsychiatric Disorders
Current Neuropharmacology The Role of the Nervous System in the Regulation of Liver Cytochrome P450
Current Drug Metabolism Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics